HMH. Cody Meissner

H. Cody Meissner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


H. Cody Meissner has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara Edge-Padbury

    1 shared publication
  • Donald Y. M. Leung

    Department of Pediatrics National Jewish Medical and Research Center University of Colorado Health Sciences Center Denver, CO 80262

    1 shared publication
  • Jon B. Bruss

    1 shared publication
  • Larry J. Anderson

    Division of Viral and Rickettsial Diseases National Center for Infectious Disease Centers for Disease Control and Prevention Atlanta, GA 30333

    1 shared publication
  • Larry K. Pickering

    National Immunization Program Centers for Disease Control and Prevention Atlanta, GA 30333

    1 shared publication
  • Margaret B. Rennels

    Department of Pediatrics University of Maryland Baltimore, MD 21201

    1 shared publication

Latest Publications

  • Influenza vaccines: a pediatric perspective

    by H Cody Meissner

    To understand the burden of disease attributable to influenza among children and to understand the basis for changing recommendations for immunization of young children. I will review the current recommendations regarding use of trivalent, inactivated influenza vaccine and live, attenuated influenza vaccine. Annual immunization of all children between 6 and 59 months of age and their household contacts is recommended starting with the 2006-2007 season, including a two-dose strategy for children under 9 years of age. Expanded recommendations are expected to reduce the number of outpatient visits, hospitalization rates and mortality rates due to influenza for both children and adults.


  • Measles Vaccines and the Potential for Worldwide Eradication of Measles

    by H. Cody Meissner, Peter M. Strebel, Walter A. Orenstein

    The annual number of reported measles cases in the United States has declined from between 3 million and 4 million in the prevaccine era to <100 cases in association with the highest recorded immunization rates in history. Because of continued importation of measles into the United States, young children who are not vaccinated appropriately may experience more than a 60-fold increase in risk of disease. Unsubstantiated claims suggesting an association between measles vaccine and neurologic disorders have led to reduced vaccine use and a resurgence of measles in countries where immunization rates have declined below the level needed to maintain herd immunity. To address the possibility of worldwide control of measles, efforts to ensure high immunization rates among people in both developed and developing countries must be sustained.


  • Annual Variation in Respiratory Syncytial Virus Season and Decisions Regarding Immunoprophylaxis With Palivizumab

    by H. Cody Meissner, Larry J. Anderson, Larry K. Pickering

    Progress in the field of passive immunoprophylaxis for protection of high-risk infants and children against respiratory syncytial virus (RSV) infection has achieved remarkable success. Palivizumab was licensed by the United States Food and Drug Administration (FDA) in 1998 for monthly intramuscular administration for prevention of RSV lower respiratory tract infections in high-risk infants and children. The annual rate of hospitalization due to RSV infection among infants in high-risk groups who do not receive immunoprophylaxis varies between 10% and 20%, a figure that is ∼5 times higher than the hospitalization rate among non–high-risk infants. Results from 2 blinded, randomized, placebo-controlled trials involving 2789 infants and children with prematurity, chronic lung disease, or congenital heart disease demonstrated a reduction in RSV hospitalization rates of between 39% and 78% in different groups.1,2 Results from postlicensure, observational studies suggest that monthly immunoprophylaxis with palivizumab may reduce rates of RSV-induced hospitalization to an even greater extent than rates reported in the well-conducted IMpact-RSV trial, which led to licensure by the FDA.3 Data confirming the safety of palivizumab have been published in a report from the FDA.4 In view of the welcome advancement in disease prevention offered by palivizumab immunoprophylaxis against the most common cause of hospitalization in the first year of life, why does controversy surround the use of this intervention? Consideration of an intervention that has been proven effective needs to include its costs and benefits and recognize that dollars spent on this intervention may …


  • Kawasaki Syndrome: Where Are the Answers?

    by H. Cody Meissner, Donald Y. M. Leung


  • Hematologic effects of linezolid in young children

    by H. Cody Meissner, Timothy Townsend, Wanda Wenman, Sheldon L. Kaplan, Maria Rayo Morfin, Barbara Edge-Padbury, Sharon Naberhuis-Stehouwer, Jon B. Bruss

    Linezolid is an effective and well-tolerated antibiotic for the treatment of Gram-positive infections, including hospital and community-acquired pneumonia and complicated and uncomplicated skin and skin structure infections. In adults linezolid treatment for >/=2 weeks has been associated with reversible hematopoietic suppression, primarily thrombocytopenia. To evaluate the occurrence of hematologic effects in children with Gram-positive infections in an open label study of linezolid vs. vancomycin. Detailed analyses of hematologic data, including reported hematologic adverse events, complete blood counts, reticulocyte index (RI) and iron studies (serum iron and transferrin saturation), were conducted in both groups at baseline and during and after treatment with the use of an intent-to-treat analysis. Three hundred sixteen patients (median age, 1.65 yr) randomized 2:1 to linezolid (n = 215) or vancomycin (n = 101) were treated. Total treatment durations were similar in the vancomycin group (12.2 +/- 6.4 days; median, 11.0 days) and the linezolid group (11.3 +/- 5.0 days; median, 11.0 days) (P = 0.20). No significant differences were noted in drug-related hematologic events, such as thrombocytopenia (linezolid, 1.9% vs. vancomycin, 0%; P = 0.170), anemia (linezolid, 1.4% vs. vancomycin, 1.0%; P = 0.771) or neutropenia (linezolid, 0% vs. vancomycin, 0%). Hemoglobin values also were similar between treatment groups when assessed by shifts from baseline to lowest recorded value. Frequency of occurrence of any substantially abnormal value for hemoglobin (15.7% vs. 12.4%), platelets (12.9% vs. 13.4%) and neutrophils (5.9% vs. 4.3%) were similar in the linezolid and vancomycin groups. No clinically relevant changes in RI or iron studies were noted between treatment groups, and parallel increases in RI occurred with both linezolid and vancomycin. No significant differences in hematologic profiles between linezolid and vancomycin occurred in this pediatric population.